Resmed Inc (RMD)
SottovalutatoFondamentale
75
Prezzo
$223.58
Capitalizzazione
$32.04B
Parte 1 · Quanto vale l'azienda
Panoramica
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Per questa società non c'è ancora una scheda redazionale
Concorrenti diretti
Con chi questa società si contende gli stessi clienti
Per questa società non c'è ancora una scheda redazionale
Per questa società non c'è ancora un elenco di concorrenti.
Stato Patrimoniale e Liquidità
Ricavi
$5.65B
Ultimi 12 mesi (al 30/06/2026)
Utile Netto
$1.52B
Ultimi 12 mesi (al 30/06/2026)
Free Cash Flow
$1.65B
Patrimonio Netto Totale
$6.59B
Passività Totali
$2.38B
Rapporto di Liquidità
3.10
Copertura Interessi
-
Debito/EBITDA
0.40
Utile per Azione
Ricavi e Utile Netto
Free Cash Flow
Scomposizione Ricavi
Prospetto storico
Margini nel tempo
Il debito nel tempo
Quanto pesa il debito
Griglia della crescita
Crescita — Ricavi
Stima del Fair Value
Fair Value
$347.45
Prezzo Attuale
$223.58
Margine di Sicurezza
+35.7%
Range Fair Value
$225.84 - $469.06
Intervallo di dispersione tra i metodi di valutazione usati, non una stima statisticamente calibrata.
Metodi di Stima
Metriche di Valutazione
Rapporto P/E
21.20
ROE
23.1%
Rapporto P/B
4.84
P/FCF
19.34
Margine Lordo
61.1%
ROIC
19.7%
Radar Redditività
Creazione di Valore (Vantaggio Competitivo)
ROIC
19.7%
WACC
8.5%
ROIC − WACC
+11.2 pp
Il ROIC supera il costo del capitale: l'azienda sta creando valore per gli azionisti.
Criteri di Analisi Fondamentale
Superati (19)
- EPS shows upward trend
- EPS CAGR 15.14%
- Price CAGR 13.41%
- ROIC 19.7%
- Gross Margin 61.1%
- P/FCF 19.34
- Debt/Equity ratio
- Operating Margin 33.4%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 23.9%
- Revenue Growth 5Y 12.1%
- PEG Ratio 0.79
- Earnings Quality (OCF/NI) 1.19
- Share Dilution -0.8%
- Piotroski F-Score 7/9
Non superati (7)
- P/B Ratio 4.84
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Analyst Consensus 48% Buy
- Earnings Surprise avg 0.8%
- Net Margin Trend 26.9% vs 27.2%
Non disponibili (2)
- Dividend Payout NaN%
- Interest Coverage
Piotroski F-Score
Salute finanziaria forte
Qualità degli Utili
Alta qualità: utili supportati da cash
Diluizione Azionaria
Riacquisto azioni. Favorevole agli azionisti
Partecipazioni istituzionali
Governance
Team Dirigenziale
| Nome | Ruolo | Età |
|---|---|---|
| Mr. Michael J. Farrell BE, MBA, SM | CEO & Chairman | 53 |
| Dr. Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScD | Founder, Chair Emeritus & Non-Executive Director | 83 |
| Mr. Michael J. Rider | Chief Legal Officer & Secretary | 67 |
| Mr. Brett A. Sandercock | Advisor | 58 |
| Mr. Justin Leong | Chief Product Officer | 47 |
| Mr. Aaron Bloomer | Chief Financial Officer | 39 |
| Mr. Alastair Robertson | Chief Information Officer | - |
| Ms. Sallilyn Schwartz | Chief Investor Relations Officer | - |
| Mr. Jim Ellis | Chief Compliance Officer | - |
| Ms. Yvonne-Katrin Pucknat | Chief Marketing Officer | 49 |
Rischio Audit
1
Rischio CdA
7
Rischio Compensi
4
Rischio Diritti Azionisti
3
Parte 2 · Il prezzo e il momento d'ingresso
Questa parte non serve a capire se l'azienda vale: serve a scegliere quando comprarla, dopo che i fondamentali ti hanno convinto. Dentro: analisi tecnica, potenziale, drawdown storici, esposizione gamma.
Documenti
- Vedi documento
Relazione annuale (10-K)
Una panoramica annuale del business, dei risultati finanziari e dei rischi dell'azienda.
Depositato il 2026-08-13
- Vedi documento
Relazione trimestrale (10-Q)
Un aggiornamento sull'andamento finanziario degli ultimi tre mesi.
Depositato il 2026-05-01
- Vedi documento
Comunicazione price-sensitive (8-K)
Una comunicazione su un evento importante, come un cambio ai vertici o un grande annuncio.
Depositato il 2026-09-01
via SEC EDGAR
Storico Ricavi
via SEC EDGAR
Ultime Notizie
Ultime notizie per RMD, da Markets Gazette.
- 3/10/2026POSITIVE3 Reasons Not to Sleep on ResMed Stock
ResMed Inc., a prominent player in the sleep apnea and respiratory care market, is highlighted for its leadership in CPAP machines and other vital medical devices. The company's focus on improving respiratory health for millions globally positions it favorably within the healthcare sector. Investors are advised not to overlook ResMed's potential, suggesting a positive outlook driven by its established market position and ongoing innovation in medical technology. The company's products address a significant and growing health concern, underpinning its long-term value proposition.
- 3/4/2026POSITIVEHere's How Much You Would Have Made Owning ResMed Stock In The Last 10 Years
ResMed Inc. (RMD) stock has delivered exceptional performance over the past 10 years, offering investors significant returns. While the article doesn't provide exact figures, the title "Here's How Much You Would Have Made" implies consistent and profitable growth. This is crucial for investors assessing the long-term potential of the medical device and sleep-care solutions sector. Past performance, while not guaranteeing future results, indicates ResMed's strong ability to generate shareholder value, potentially driven by product innovation, market expansion, and sound management.
via Markets Gazette